ELISpot and FluoroSpot Assay Market Research Report – Global Forecast till 2030

ELISpot and FluoroSpot Assay Market Research Report, by Product (Assay Kit, Ancillary Products), Application (Transplant, Vaccines), End-User (Hospitals and Clinics, Ambulatory Surgical Centres, Diagnostic Centres, Research Centers) – Forecast Till 2030

ID: MRFR/LS/5483-HCR | February 2023 | Region: Global | 90 Pages         

ELISpot and FluoroSpot Assay Market Speak to Analyst Request a Free Sample

ELISpot and FluoroSpot Assay Market

ELISpot and FluoroSpot Assay Market is expected to register a CAGR of 16.1% and was valued at USD 710.03 Million.

Segmentation
By Product Assay Kit Ancillary Products
Application Transplant Vaccines
End-User Hospitals and Clinics Ambulatory Surgical Centres Diagnostic Centres Research Centers
Key Players
Companies Profiled   Oxford Immunotec (UK)    Cellular Technologies (US)    Mabtech (Sweden)    Becton    Dickinson and Company (US)    and Abcam (UK)Bio-Techne (US)    Autoimmun Diagnostika (Germany)    Biotech Investissement (France)    Lophius Biosciences (Germany)    and U-CyTech (Netherlands)    and Others
Drivers
Market Driving Forces   Increasing incidence of chronic diseases   Rising vaccine development
Request a Free Sample

ELISpot and FluoroSpot Assays Market Overview The ELISpot and FluoroSpot Assay Market were estimated CAGR of 16.1% during the forecast period. ELISpot and FluoroSpot Assays are sensitive methods for detecting immune cells that contain specific proteins like cytokines or antibodies. These tests are used in hospitals and research centers to detect diseases like tuberculosis and other viral infections early. The FluoroSpot assay is a variation of the ELISpot assay that uses a combination of monoclonal antibodies and other reagents to detect infection. The rising incidence of chronic diseases, rising vaccine development to address the challenge of antibiotic resistance, and technological developments in analyzers and ELISpot and FluoroSpot assay kits are all driving market expansion. ELISpot is a critical step in the development of vaccines for a variety of diseases, including AIDS, TB, HIV, malaria, cancer, and influenza. The ELISpot test is one of the most extensively used immunoassays in vaccine evaluation studies. The FluoroSpot test combines the sensitivity of ELISpot with the capacity to evaluate multi-analyte secretion simultaneously, allowing cell population studies with varying operational parameters. The better sensitivity of the sample, statistical read-out, and convenience of use in both broad screening and individual testing contributed to this reputation. Both T-cell responses and vaccine-specific antibody-producing B cells can be assessed with this technique. As a result of the aforementioned factors, the cancer therapy market is predicted to rise rapidly over the forecast period.

Segmentation:


The ELISpot and FluoroSpot Assay Market is segmented on the basis of product, application, and end-user. The market, by product is categorised into various assay kit, analyzer, ancillary products. The assay kit is sub-segmented into T Cell assay and B Cell assay. On the basis of application, the market is segmented into transplant, vaccines development, clinical trials, cancer treatment. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.


On the basis of region, the ELISpot and FluoroSpot Assay Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players:


Some of the key players in the ELISpot and FluoroSpot Assay Market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others.


Regional Market Summary: ELISpot and FluoroSpot Assay Market Share


Global ELISpot and FluoroSpot Assay Market Share (%), by Region, 2017


Sources: National Cancer Institute, Cancer research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of HealthIt is estimated that North America dominated the ELISpot and FluoroSpot Assay Market owing to the increasing cardiac diseases, innovations in clinical practice, increasing research and development in pharmaceutical industries boost the market growth. According to the Centers for Disease Control and Prevention 2017 publication 83.4% of children aged 19-35 months were vaccinated with Diphtheria, Tetanus, Pertussis in the US. The increasing demand for vaccines will boost the market growth.


Europe stood second largest in the ELISpot and FluoroSpot Assay market owing to the increasing number of pharmaceutical companies, rising in the development of innovative vaccines for the treatment of various viral diseases. The growing funding from government and private agencies for drug development also support the market in this region.  Asia-Pacific was estimated to be the fastest growing region for the Market in 2017. The market is expected to witness growth owing to the rising prevalence of viral infection, increasing geriatric population in this region and growing demand for ELISpot and FluoroSpot Assay in research field.


The Middle East and Africa holds the least share in the ELISpot and FluoroSpot Assay Market due to the presence of low health expenditure, lack of skilled technicians and less pharmaceutical company in this region. However, the market is expected to witness growth due to increasing research & development in the Middle East.


Market Segmentation and Key Market Players:


ELISpot and FluoroSpot Assay Market, by Product:



  • Assay Kit


    •  T Cell assay

    • B Cell assay


  • Analyzer

  • Ancillary Products 


ELISpot and FluoroSpot Assay Market, by Application:



  • Transplant,

  • Vaccines

  • Clinical Trials

  • Cancer Treatment


ELISpot and FluoroSpot Assay Market, by End-Users:



  • Hospitals and clinics

  • Ambulatory surgical centers

  • Diagnostic centers

  • Research centers

  • Others


ELISpot and FluoroSpot Assay Market, by Region:



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa 


Recent Development


ImmunoSpot introduced SpotStat Software in September 2021 for statistical analysis of ELISPOT/FluoroSpot data. The major purpose of SpotStat is to give statistically confirmed antigen-induced and negative controls differentiation. Ardigen and ImmuMap began collaborating on research in April 2021. The collaboration between ImmuMap and Ardigen will focus on finding T-cell receptors (TCRs) that are reactive to tumor-associated neoantigens. The researchers will use ELISpot assays (enzyme-linked immunosorbent assays), next-generation sequencing (NGS), MHC multimer labeling and sorting, and 10x Genomics Single Cell Immune Profiling.

Intended Audience:



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 287 million
  CAGR   16.1 %
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Product, Application, End-User & Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others.
  Key Market Opportunities   Increasing research & development investments by industry players
  Key Market Drivers

  • Increasing incidence of chronic diseases
  • rising vaccine development


  • Speak to Analyst Ask for Customization